Welcome to Multibagg AI
Log in to access personalized features
Bearish
7
Neutral
2
Bullish
5
Bearish
11
Neutral
2
Bullish
33
Bearish
4
Neutral
0
Bullish
28
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Trimurthi Limited, originally a financial and securities company, transitioned into pharmaceuticals and drugs, marking significant industry diversification.
The company operates pharmacy retail outlets in Hyderabad and has expanded its operations in West Bengal and Assam, indicating a strategic geographic expansion in India.
Trimurthi Limited has also commenced operations in the food industry through a wholly-owned subsidiary, signaling diversification beyond pharmaceuticals.
The company received ISO 9001:2008 certification, demonstrating a commitment to quality in its pharmaceutical marketing and distribution processes.
Healthcare Services
Healthcare Research, Analytics & Technology
59 Cr
Low Risk
-27.0
58.6
—
3.2
92.00
29.33
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Novelix Pharmaceuticals Ltd (TRIMURTHI) is currently trading at 84.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Trimurthi Limited, originally a financial and securities company, transitioned into pharmaceuticals and drugs, marking significant industry diversification. The company operates pharmacy retail outlets in Hyderabad and has expanded its operations in West Bengal and Assam, indicating a strategic geographic expansion in India. Trimurthi Limited has also commenced operations in the food industry through a wholly-owned subsidiary, signaling diversification beyond pharmaceuticals. The company received ISO 9001:2008 certification, demonstrating a commitment to quality in its pharmaceutical marketing and distribution processes.
Over the past 52 weeks, Novelix Pharmaceuticals Ltd has traded between a low of ₹29.33 and a high of ₹92.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Novelix Pharmaceuticals Ltd has a market capitalization of approximately 58.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Novelix Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -27.02 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 58.64 Cr, Novelix Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Novelix Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Novelix Pharmaceuticals Ltd is -27.02. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
77.11 | 157 Cr | -978.50 | 2.18 | 0.00 | 1.60 | 4.43 | 0.97 | ||
57.50 | 135 Cr | -74.41 | 0.69 | 0.00 | 2.81 | 6.68 | -3.69 | ||
24.75 | 85 Cr | 29.67 | 1.48 | 0.00 | 5.01 | 4.64 | 4.27 | ||
87.50 | 59 Cr | -27.02 | 3.24 | 0.00 | -30.18 | -32.45 | -30.18 | ||
15.00 | 22 Cr | 12.47 | 1.44 | 0.00 | 0.00 | 0.00 | 2.57 | ||
23.75 | 17 Cr | 153.55 | 0.80 | 0.00 | 0.51 | 1.31 | 0.17 | ||
39.55 | 12 Cr | -8.46 | 1.49 | 0.00 | -17.77 | 0.86 | -3.87 | ||
| Median: 7 Co. | — | 39.55 | 59 Cr | -8.46 | 1.48 | 0.00 | 0.51 | 1.31 | 0.17 |
Preferential Allotment Corrigendum
Novelix Pharmaceuticals issued a corrigendum (17 Jun 2026) to its EGM notice (01 Jul 2026) revising Item 1: two proposed allottees are disqualified for selling shares within 90 days; 175,000 shares are reallocated among other proposed allottees and a name typo is corrected.
EGM Corrigendum
Novelix issues corrigendum to the 01-Jul-2026 EGM notice revising Item 1: two proposed allottees disqualified from preferential allotment for share sales within 90 trading days, 175,000 shares reallocated to other allottees and a name typo corrected.
